Oral TRT Compared: Jatenzo vs Kyzatrex vs Tlando

What's the short answer?

The short answer: Modern oral TRT — Jatenzo, Kyzatrex, and Tlando — is a credible needle-free option for the right patient. All three deliver testosterone undecanoate by intestinal lymphatic absorption, all three require a meal containing fat, and all three carry the same FDA-required blood pressure warning. They differ in titration flexibility (Jatenzo and Kyzatrex titrate; Tlando is fixed-dose), dosing schedule (twice daily across the board), and cost.

For an oral TRT comparison, the practical decision rarely comes down to which molecule is "better" — it's the same molecule. It comes down to whether the dose can be titrated to your blood work, whether your eating pattern reliably includes fat at the dosing windows, and what your insurance will actually cover. None of the three is a substitute for proper diagnosis, monitoring, or the safety conversations that should accompany any testosterone prescription per the Endocrine Society and AUA guidelines.

What modern oral TRT actually is

Oral testosterone has a complicated history. First-generation oral androgens like methyltestosterone were 17-alpha-alkylated to survive first-pass hepatic metabolism. That alkylation produced the well-documented liver toxicity that effectively retired oral testosterone for decades and is the reason most clinicians grew up assuming "oral TRT is dangerous to the liver."

Modern oral TRT is a different molecule with a different absorption pathway. Testosterone undecanoate is testosterone esterified to a long-chain (C-11) fatty acid. When taken orally with food, the lipophilic ester is incorporated into chylomicrons in the intestine and absorbed through the lymphatic system, bypassing first-pass hepatic metabolism. Enzymes in the bloodstream then cleave the ester to release free testosterone. The Jatenzo Phase III safety data (Swerdloff RS et al., Journal of Clinical Endocrinology & Metabolism 2020, PMID 31760430) and the Kyzatrex pivotal trial published in PMC (PMC8826129) both showed liver enzyme profiles indistinguishable from baseline over 12 months of dosing.

The three FDA-approved products

1. Jatenzo (testosterone undecanoate, Clarus Therapeutics) — FDA-approved March 2019. Twice-daily capsules with multiple titration strengths.
2. Kyzatrex (testosterone undecanoate, Marius Pharmaceuticals) — FDA-approved July 2022. Twice-daily SEDDS (self-emulsifying drug delivery system) capsules with multiple titration strengths.
3. Tlando (testosterone undecanoate, Antares Pharma / Halozyme) — FDA-approved March 2022 after a long regulatory path. Twice-daily fixed-dose capsule (no titration).

How oral TRT serum levels look across a day

The chart below illustrates the within-day pattern of testosterone after a twice-daily oral undecanoate dose taken with breakfast and dinner. Compared with weekly cypionate injections, the cycle is much shorter — peak and trough happen on the order of hours rather than days.

Side-by-side comparison

Jatenzo: the first reborn oral TRT

Jatenzo (testosterone undecanoate) was the first modern oral testosterone approved by the FDA, in March 2019. Approval was based on a Phase III pivotal trial published by Swerdloff and colleagues in the Journal of Clinical Endocrinology & Metabolism (PMID 31760430). The trial enrolled hypogonadal men with confirmed low total testosterone and titrated Jatenzo across multiple dose strengths over 4 months, with safety follow-up out to 12 months.

Pharmacology and dosing

• Strengths: 158 mg, 198 mg, 237 mg capsules, allowing fine titration in both directions.
• Schedule: Twice daily — morning and evening — with food.
• Titration: Total testosterone is measured roughly 6 hours after the morning dose at the next clinic visit; dose is adjusted up or down based on the result.
• Steady state: Reached within days, given the short within-day cycle.

Efficacy data

In the Jatenzo Phase III trial, 87 percent of men achieved an average serum testosterone within the eugonadal range after dose titration (Swerdloff RS et al., JCEM 2020). Mean total testosterone in completers landed in the mid-normal range. PSA, hematocrit, and lipid changes were modest and consistent with the broader TRT literature summarized in the TRAVERSE trial review.

Safety signals

The most important safety finding was a small but consistent rise in ambulatory blood pressure — roughly 4-5 mmHg systolic on average — across the dose range. This signal was severe enough that the FDA required a boxed-style warning on the Jatenzo label. Liver enzyme changes were not clinically meaningful, putting modern oral TRT in a fundamentally different safety category from old 17-alpha-alkylated oral androgens.

Kyzatrex: the twice-daily SEDDS option

Kyzatrex (testosterone undecanoate, Marius Pharmaceuticals) received FDA approval in July 2022. The pivotal trial supporting approval — published and indexed at PMC8826129 — used a self-emulsifying drug delivery system (SEDDS) formulation designed to standardize lymphatic absorption across patients and meal types.

Pharmacology and dosing

• Strengths: 100 mg, 150 mg, 200 mg capsules.
• Schedule: Twice daily with food. The label allows starting at 200 mg twice daily and titrating to total testosterone after the morning dose.
• SEDDS technology: The capsule excipients are designed to self-emulsify on contact with intestinal contents, theoretically reducing the day-to-day absorption variability that has historically plagued lymphatic-route drugs.
• Steady state: Reached within days, like Jatenzo.

Efficacy and safety

The Kyzatrex pivotal trial reported that the majority of titrated participants achieved average serum testosterone within the eugonadal range, with safety findings broadly consistent with the Jatenzo data: small ambulatory blood pressure increases on the order of 4-5 mmHg, no clinically meaningful liver enzyme changes, and modest hematocrit shifts within the range expected for any TRT modality. As with all TRT, hematocrit monitoring follows the AUA threshold framework discussed in our hematocrit on TRT piece.

Tlando: the fixed-dose oral capsule

Tlando (testosterone undecanoate, originally developed by Lipocine as LPCN-1021) had a long regulatory path before earning FDA approval in March 2022. The defining feature of Tlando is that it is fixed-dose: every patient takes the same 112.5 mg capsule twice daily, with no titration step.

Pharmacology and dosing

• Strength: 112.5 mg capsule (fixed).
• Schedule: Two capsules twice daily with food — a standard 225 mg twice-daily total dose for everyone.
• Titration: None. Either the fixed dose places you in the therapeutic range or it does not.
• Implication: The label does not require routine post-dose serum testosterone for titration in the way that Jatenzo and Kyzatrex labels do. Standard TRT monitoring still applies — see the AUA 2018 guideline framework.

Trade-offs of a fixed-dose oral

• Simplicity wins: Adherence is easier. No dose conversations, no strength changes, no pill-counting confusion.
• Flexibility loses: Patients who land too high or too low on the fixed dose have nowhere to go within Tlando — the choice is to switch products entirely or accept the result.
• SHBG matters: Men with very high or very low SHBG often need protocol adjustments to land free testosterone correctly, and a fixed-dose oral has no lever for that.

The shared blood pressure warning

Every modern oral TRT carries the same FDA-required blood pressure warning. This is the single most important safety distinction between oral TRT and injectable testosterone cypionate or transdermal gel, and it should drive prescribing decisions more than brand selection.

What the data show

Across the Jatenzo (Swerdloff et al. JCEM 2020) and Kyzatrex pivotal trial (PMC8826129) datasets, average ambulatory systolic blood pressure rose by roughly 3-5 mmHg from baseline, with somewhat larger increases in subsets of patients. The mechanism is not fully characterized but likely involves a combination of mineralocorticoid effects, modest fluid shifts, and erythrocytosis-related viscosity changes. The trials did not find a corresponding mortality or hard cardiovascular endpoint signal — they were not powered for that — and the larger TRAVERSE trial on injectable TRT did not show a MACE non-inferiority concern at the population level.

What the labels require

• Pre-prescription assessment: Document baseline blood pressure (multiple office or ambulatory readings).
• Avoid in uncontrolled hypertension: The labels caution against initiating oral testosterone undecanoate in patients with uncontrolled BP.
• Re-check on therapy: A blood pressure check within roughly 6 weeks of starting, then at routine TRT visits.
• Treat or de-prescribe: If blood pressure rises clinically meaningfully on therapy, optimize antihypertensive treatment or discontinue oral TRT.

Labs and monitoring on oral TRT

Monitoring on oral TRT borrows the standard TRT blood work schedule with a few oral-specific adjustments. The Endocrine Society 2018 and AUA 2018 guideline frameworks remain the backbone.

Oral-specific draw timing

• Total testosterone: The Jatenzo and Kyzatrex labels specify drawing total testosterone roughly 6 hours after the morning dose for titration. This timing reflects the average within-day curve.
• Free testosterone and SHBG: Add to the panel routinely; SHBG status meaningfully changes free testosterone interpretation on any TRT modality.
• Estradiol (sensitive E2): Order with the same panel. Aromatization rates on oral undecanoate are not categorically different from injectables, but patients with elevated body fat or insulin resistance may run higher E2 — see our estradiol on TRT piece for sensitive E2 ranges and decision rules.
• Hematocrit and CBC: Standard monitoring per AUA. The 54 percent threshold from the AUA guideline applies.
• PSA: Per AUA in men 40 and older or with prostate cancer risk factors.
• Blood pressure: The label-required check that distinguishes oral TRT monitoring from gel and injection monitoring.

Monitoring intensity comparison

Oral TRT carries the highest blood pressure monitoring intensity of any TRT modality because of the FDA label requirement. Injections carry the highest hematocrit monitoring intensity because erythrocytosis risk scales with peak serum testosterone. Pellets carry the most front-loaded draw-timing complexity because of the sharp peak after implantation. Gel sits in the middle on most axes.

Cost and access

For a strict oral TRT comparison on cost, all three are dramatically more expensive than generic injectable testosterone cypionate, which routinely runs $30-80 per month at retail pharmacies. Manufacturer copay programs are real and meaningful for commercially insured patients, but Medicare and Medicaid restrictions vary, and step-therapy requirements are common across commercial plans.

Who should choose which

Oral TRT (any of the three) may be the right fit if you:

• Genuinely cannot tolerate injections, even subcutaneous, and have already considered gel as an alternative.
• Live in a household where transdermal transfer of gel to a partner, child, or pet is a real concern.
• Have predictable eating patterns that include a meal with at least 15-30 grams of fat at the dosing windows.
• Have controlled blood pressure with documented baseline readings.
• Have insurance coverage or a manufacturer copay program that makes the monthly cost manageable.
• Are willing to commit to twice-daily dosing as a long-term routine.

Jatenzo specifically may be best if you:

• Need fine titration to a specific total or free testosterone target (the 158/198/237 mg ladder gives clinicians multiple steps).
• Want the longest-running real-world use data among the three (Jatenzo has been on market since 2019).
• Have a prescriber familiar with the original Phase III titration protocol (Swerdloff et al. JCEM 2020, PMID 31760430).

Kyzatrex specifically may be best if you:

• Want titration flexibility (100/150/200 mg) plus the SEDDS formulation argument for steadier absorption.
• Have a prescriber who has adopted Kyzatrex as their default oral TRT.
• Are starting fresh and want the newest formulation without strong reasons to prefer Jatenzo.

Tlando specifically may be best if you:

• Value adherence simplicity over titration flexibility.
• Are likely to land in the eugonadal range on a standardized fixed dose (a question your prescriber and your blood work answer).
• Are comfortable switching products if the fixed dose places you outside target.

Oral TRT may not be the right fit if you:

• Skip breakfast, follow a low-fat diet, or eat unpredictably.
• Have uncontrolled or borderline hypertension.
• Are cost-sensitive and have access to generic injectable testosterone cypionate.
• Want fertility preservation (no exogenous testosterone — oral or otherwise — preserves spermatogenesis without an adjunct like HCG).
• Prefer once-weekly or twice-weekly dosing over twice-daily.

The bottom line

Modern oral TRT — Jatenzo, Kyzatrex, and Tlando — is a legitimate, FDA-approved, evidence-backed option for men who cannot or will not use injections, gel, or pellets. The Jatenzo Phase III data (Swerdloff et al., JCEM 2020, PMID 31760430), the Kyzatrex pivotal trial (PMC8826129), and the Tlando registration program established that testosterone undecanoate delivered through intestinal lymphatic absorption can produce eugonadal serum levels with a safety profile that is fundamentally different from old 17-alpha-alkylated oral androgens.

The three brands share the same molecule, the same food requirement, and the same FDA blood pressure warning. They differ on titration flexibility, manufacturer, and cost. For most patients, the more meaningful decision is whether oral TRT is the right modality — not which oral brand to use. Use the comparison framework above with your prescriber and your blood work to decide. And use the standard TRT blood work schedule as the backbone of monitoring, with the oral-specific blood pressure check layered on top.

Whichever path you choose, the fundamentals do not change: confirmed diagnosis with two morning total testosterone draws, a baseline panel that includes sensitive estradiol, ongoing monitoring per AUA and Endocrine Society guidelines, and a prescriber who treats blood pressure and hematocrit as mandatory — not optional — parts of TRT care.